The effect of one injection of Depo-Provera® on the human vaginal epithelium and cervical ectopy

Contraception

Volumn 60, Issue 1, 1999, Pages 15-24

  Mauck, Christine K ^a   Callahan, Marianne Morse ^a   Baker, Jay ^b   Arbogast, Kathleen ^b   Veazey, Ron ^c   Stock, Richard ^d   Pan, Zhiying ^e   Morrison, Charles S ^e   Chen Mok, Mario ^e   Archer, David F ^b   Gabelnick, Henry L ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^e FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

Biopsy; Cervix; Contraceptive; Depo Provera; Ectopy; Epithelium; Estra diol; Injectable; Medroxyprogesterone acetate; Progesterone; Vagina

Indexed keywords

ESTRADIOL; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

ADULT; ARTICLE; BIOPSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ECTOPIC TISSUE; FEMALE; FOLLICULAR PHASE; HORMONAL CONTRACEPTION; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; INFECTION RISK; INTRAMUSCULAR DRUG ADMINISTRATION; LANGERHANS CELL; LUTEAL PHASE; NORMAL HUMAN; SIMIAN IMMUNODEFICIENCY VIRUS; UTERINE CERVIX; VAGINA CYTOLOGY; VAGINA EPITHELIUM;

AMERICAS; BIOLOGY; CERVICAL EFFECTS; CERVIX; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE--SIDE EFFECTS; CONTRACEPTIVE AGENTS, PROGESTIN--SIDE EFFECTS; CONTRACEPTIVE AGENTS--SIDE EFFECTS; DEPO-PROVERA--SIDE EFFECTS; DEVELOPED COUNTRIES; DISEASES; FAMILY PLANNING; GENITALIA; GENITALIA, FEMALE; MEDROXYPROGESTERONE ACETATE--SIDE EFFECTS; NORTH AMERICA; NORTHERN AMERICA; PHYSIOLOGY; RESEARCH REPORT; UNITED STATES; UROGENITAL SYSTEM; UTERUS; VAGINAL ABNORMALITIES; VIRGINIA;

ADULT; BIOPSY; BODY WEIGHT; CERVIX UTERI; CONTRACEPTIVE AGENTS, FEMALE; EPITHELIUM; ESTRADIOL; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INJECTIONS, INTRAMUSCULAR; LANGERHANS CELLS; MEDROXYPROGESTERONE 17-ACETATE; MENSTRUAL CYCLE; PHOTOGRAPHY; PROGESTERONE; REGRESSION ANALYSIS; STATISTICS, NONPARAMETRIC; VAGINA;

EID: 0032723177     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(99)00058-X     Document Type: Article

References (21)

1. Piccinino LJ, Mosher WD. Trends in contraceptive use in the United States. Fam Plann Perspec 1998;30:4-10,46.
2. Marx P.A., Spira A.I., Gettie A., et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nature Medicine. 10:1996;1083-1089.
3. Parr MB, Kepple L, McDermott MR, Drew MD, Bozzola JJ, Parr EL. A mouse model for studies of immunity to vaginal infection by herpes simplex virus type 2. Lab Invest 1994;70,369-80.
4. Ungchusak K., Rehle T., Thammapornpilap P., Spiegelman D., Brinkman U., Siraprapasiri T. Determinants of HIV infection among female commercial sex workers in Northeastern Thailand results from a longitudinal study . J Acquir Immun Defic Syndr. 12:1996;500-507.
5. Rehle T., Brinkmann U.K., Siraprapasiri T., et al. Risk factors of HIV-1 infection among female prostitutes in Khon Kaen, Northeast Thailand. Infection. 20:1992;328-331.
6. Martin HL, Nyange PM, Richardson BA, et al. Hormonal contraception, sexually transmitted disease, and risk of heterosexual transmission of HIV-1. J Infect Dis (in press).
7. Brabin L., Kemp J., Obunge O.K., et al. Reproductive tract infections and abortion among adolescent girls in rural Nigeria. Lancet. 345:1995;300-304.
8. Nagachinta T., Duerr A., Suriyanon V., Nantachit N., et al. Risk factors for HIV-1 transmission from HIV-seropositive male blood donors to their regular female partners in northern Thailand. AIDS. 11:1997;1765-1772.
9. Kapiga S.H., Lyamuya E.F., Lwihula G.K., Hunter D.J. The incidence of HIV infection among women using family planning methods in Dar es Salaam, Tanzania. AIDS. 12:1998;75-84.
10. Thiery M., Vandekerckhove D., Dhont M., Vermeulen A., Decoster J.M. The medroxyprogesterone acetate intravaginal Silastic ring as a contraceptive device. Contraception. 13:1976;605-617.
11. Hornemann B., Osler M. Medroxyprogesterone acetate as a contraceptive. Int J Fertil. 17:1972;210-216.
12. Ringrose C.A. Effects of medroxyprogesterone acetate employed as a long-term injectable contraceptive. J Reprod Med. 8:1972;75-79.
13. Mishell D.R. Jr, Talas M., Parlow A.F., Moyer D.L. Contraception by means of a Silastic vaginal ring impregnated with medroxyprogesterone acetate. Am J Obstet Gynecol. 107:1970;100-107.
14. Fawcett D.W. A Textbook of Histology. 1994;857 Chapman and Hall, New York.
15. Goldacre M.J., Loudon N., Watt B., et al. Epidemiology and clinical significance of cervical erosion in women attending a family planning clinic. Br Med J. 1:1978;748-750.
16. Harrison H.R., Costin M., Meder J.B., et al. Cervical chlamydia trachomatis infection in university women relationship to history, contraception, ectopy and cervicitis . Am J Obstet Gynecol. 153:1985;244-251.
17. Louv W.C., Austin H., Perlman J., Alexander W.J. Oral contraceptive use and the risk of chlamydial and gonococcal infections. Am J Obstet Gynecol. 60:1989;396-402.
18. Rahm V.A., Odlind V.F., Petterson R. Chlamydia trachomatis in sexually active teenage girls. Factors related to genital C. trachomatis a prospective study . Genitourin Med. 67:1991;31-32.
19. Critchlow C.W., Wolner-Hanssen P., Eschenbach D.A., et al. Determinants of cervical ectopia and of cervicitis age, oral contraception, specific cervical infection, smoking, and douching . Am J Obstet Gynecol. 173:1995;534-543.
20. Winter L., Goldy A.S., Baer C. Prevalence and epidemiologic correlates of Chlamydia trachomatis in rural and urban populations. Sex Transm Dis. 17:1990;30-36.
21. Hild-Petito S., Veazey R.S., Larner J.M., Reel J.R., Blye R.P. Effects of two progestin-only contraceptives, Depo-Provera and Norplant-II, on the vaginal epithelium of rhesus monkeys. AIDS Res Hum Retrovir. 14S:1998;125-130.